Sponsored

Here’s what you need to know about Invion’s (ASX:IVX) world-leading partners in its mission to treat cancers 

More on:

Image Source: Invion Website

Highlights

  • Invion is committed to developing PhotosoftTM technology, the next-generation Photodynamic Therapy (PDT) to treat a range of cancers, atherosclerosis and infectious diseases.
  • Novel PDT photosensitiser INV043 has demonstrated immune response, protective immunity, and a strong therapeutic profile, in addition to the regression of established tumours.
  • Collaboration with world-class expertise, including Hudson Institute and Peter MacCallum Cancer Centre has given a leg up to the Company’s ongoing endeavours.

Invion Limited (ASX:IVX) is rapidly advancing its next-generation photodynamic therapy, PhotosoftTM technology, to treat a range of cancers, atherosclerosis and infectious diseases. The Company is forging ahead with its research & development, with recent outcomes exhibiting exciting potential.

In recent Proof of Concept (PoC) Studies, novel PDT photosensitiser INV043 has demonstrated to trigger an immune response in the body, protective immunity, and has a strong therapeutic profile in addition to killing the tumours.

The studies used INV043 and active pharmaceutical ingredient (API) to treat healthy mice that had been implanted with triple negative breast cancer (TNBC).

Source: IVX Presentation, dated 3 February 2022

ALSO READ: All you need to know about Invion’s (ASX:IVX) journey to develop cancer treatment

The Company is not working alone. Collaboration with world-class expertise has given a leg up to its ongoing endeavours.

Let us look at these institutions and how are they helping Invion.

Hudson Institute of Medical Research

Global bioscience medical research institute, Hudson has more than 400 scientists focused on ground-breaking discoveries addressing complex problems in human diseases, including cancer.

PhotosoftTM discovery and development are advanced by Hudson, including PoC studies focused on safety and efficacy.

Invion has indicated that its research partner is advancing translational work into clinical trial preparations, PoC work undertaken on INV043 to study its effect on immune response as well as exploring the ability to work along with other therapies.

ALSO READ: Invion closes December quarter on firm financial footing and promising drug development outlook

Peter MacCallum Cancer Centre

Peter MacCallum Cancer Centre is a world-class institute that boasts the ability to translate its premier cancer research capability directly into the clinic.

The centre is currently conducting about 500 clinical trials in cancer while pre-clinical studies initially focus on high-risk anogenital cancers. Successful studies will pave the way for human clinical trials.

The centre’s expertise is expected to provide broader and long-term opportunities to Invion.

ALSO READ: A deep dive into Invion’s (ASX:IVX) opportunities in cancer and AID space

The RMW Cho Group

The inventor and licensor of PhotosoftTM technology, The RMW Cho Group, has appointed Invion as the exclusive distributor and licensee in  of the technology in several markets across APAC. The Group has funded and successfully commercialised several unique and advanced technologies.

Invion has an agreement with RMW Cho Group to conduct the clinical development of PhotosoftTM technology globally for treating cancer, with the latter providing non-dilutive funding for the research and clinical trials of the technology through an R&D services agreement with Invion.

ALSO READ: Invion (ASX:IVX) making inroads into treatment of atherosclerosis and infectious diseases

Invion is committed to the commercialisation of the next-generation PDT treatment for major diseases, including cancer. The Company is backed by strong partners that hold incredibly strong knowledge and expertise to bring the technology to the next level.  

IVX shares were trading at AU$0.016 midday on 24 March 2022.  


 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and